Josh Doloff

Joshua C. Doloff, PhD

Assistant Professor

Assistant Professor of Biomedical Engineering, and Materials Science & Engineering

Office: Smith 5027
Lab: Doloff Lab for Immunoengineering & Regenerative Medicine


Postdoctoral Fellowship, Langer/Anderson Labs, Koch Institute, MIT (2011-2018)
PhD, Molecular, Cellular Biology & Biochemistry, Boston University (2011)
MA, Molecular, Cellular Biology & Biochemistry, Boston University (2011)
BSE, Bioengineering, University of Pennsylvania (2004)

Research Interests

Dr. Doloff’s lab in Immunoengineering and Regenerative Medicine is interested in systems biology for understanding tissue dynamics pertaining to immunologic engagement, with applications in biomaterial/biomedical devices, controlled drug delivery systems, and synthetic cellular engineering. Specific emphasis will be applied toward engineering improved therapies in the fields of cancer, autoimmunity and transplantation medicine (i.e. type 1 diabetes), and ophthalmology.

Selected Publications

From Pub Med   |   Google Scholar Profile

Publications Search

Farah S*, Doloff JC*, Mueller P, Sadraei A, Han HJ, Olafson K, Tyas K, Tam HH, Hollister-Locke J, Griffin M, Meng A, McGarrigle J, Greiner DL, Weir G, Oberholzer J, Langer R, and Anderson DG. 2018. Long-Term Implant Fibrosis Prevention in Rodents and Non-Human Primates Using Crystallized Drug Formulations (Accepted, in press Nature Materials).

Bochenek MA, Veiseh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E, Omami M, Doloff JC, Mendoza-Elias J, Nourmohammadzadeh M, Khan A, Yeh C, Isa D, Ghani S, Li J, Landry C, Bader AR, Olejnik K, Chen M, Hollister-Lock J, Wang Y, Greiner DL, Weir GC, Strand BL, Rokstad AM, Lacik I, Langer R, Anderson DG, and Oberholzer J. 2018. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nature Biomedical Engineering. 2018 Aug 13. doi: 10.1038/s41551-018-0275-1.

Khan OF, Kowalski P*, Doloff JC*, Tsosie JK, Bakthavatchalu V, Bodi CW, Haupt J, Jamiel M, Langer R, and Anderson DG. 2018. Targeted gene knockdown in the vasculature of nonhuman primates using optimized low molecular weight polyethylenimine-based amphiphiles. Science Advances. 2018 Jun 27;4(6):eaar8409. doi: 10.1126/sciadv.aar8409.

Xie X*, Doloff JC*, Yesilyurt V*, Sadraei A*, McGarrigle J, Omami M, Veiseh O, Isa D, Ghani S, Joshi I, Li J, Wang W, Tam HH, Tao J, Chen H, Yang B, Oberholzer J, Langer RS, Anderson DG. 2018. Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer. Nature Biomedical Engineering. 2018 July 30. doi: 10.1038/s41551-018-0273-3.

Doloff JC, Veiseh O, Vegas AJ, Tam HH, Farah S, Ma M, Li J, Bader A, Chiu A, Sadraei A, Aresta-Dasilva S, Griffin M, Jhunjhunwala S, Webber M, Siebert S, Tang K, Chen M, Langan E, Dholokia, Thakrar R, Qi M, Oberholzer J, Greiner DL, Langer R, and Anderson DG. 2016. Colony Stimulating Factor-1 Receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nature Materials. 2017 Mar 20. doi: 10.1038/nmat4866.

Vegas AJ, Veiseh O, Doloff JC, Ma M, Tam HH, Bratlie K, Li J, Bader A, Langan E, Olejnik K, Fenton P, Kang JW, Hollister-Locke J, Bochenek MA, Chiu A, Siebert S, Tang K, Jhunjhunwala S, Aresta-Dasilva S, Dholokia N, Thakrar R, Vietti T, Cohen J, Siniakowicz K, Qi M, Lyle S, Harlan DM, Greiner DL, Oberholzer J, Weir GC, Langer RS, and Anderson DG. 2016. Combinatorial development of hydrogels that mitigate the foreign body response in primates. Nature Biotechnology. Mar;34(3):345-52. doi:10.1038/nbt.3462.

Vegas AJ, Veiseh O, Gurtler M, Millman J, Paglicua F, Bader A, Doloff JC, Li J, Chen M, Olejnik K, Tam HH, Jhunjhunwala S, Langan E, Aresta-Dasilva S, Gandham S, Greiner DL, Weir GC, Melton DA, Langer R, and Anderson DG. 2016. Long term glycemic control using polymer encapsulated, human stem cell derived b-cells in immune competent rodents. Nature Medicine. Mar;22(3):306-11. doi:10.1038/nm.4030.

Veiseh O*, Doloff JC*, Ma M*, Vegas AJ, Tam HH, Bader AR, Li J, Langan E, Wyckoff J, Loo WS, Jhunjhunwala S, Chiu A, Siebert S, Tang K, Hollister-Locke J, Aresta-Dasilva S, Bochenek M, Mendoza-Elisa J, Wang Y, Qi M, Lavin D, Chen M, Dholokia N, Thakrar R, Lacik I, Weir GC, Oberholzer J, Greiner DL, Langer R, and Anderson DG. 2015. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nature Materials, Jun; 14(6):643-51.

Doloff JC*, Chen CS*, and Waxman DJ. 2014. Anti-tumor innate immunity activated by metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Molecular Cancer, Jun 26; 13(1): 158.

Chen CS*, Doloff JC*, and Waxman DJ. 2014. Intermittent metronomic drug schedule is essential for activating anti-tumor innate immunity and tumor xenograft regressionNeoplasia, Jan; 16(1): 84-96.

Doloff JC and Waxman DJ. 2012. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression, Cancer Research, Mar 1; 72(5): 1103-15.